US Government's New Investment: Developing Treatments for Rare Diseases

The US government recently announced a significant investment in the development of treatments for rare diseases. This is their tangible response to the question of whether it's possible to create medicine even for a single patient. Over the next five years, they plan to invest up to $160 million, approximately 220 billion Korean won, to develop personalized therapies for rare genetic disorders.

The Reality and Limitations of Rare Diseases

While over 10,000 rare diseases are currently known, only about 5% have received FDA approval. In the US, there are 25 to 30 million people living with rare diseases, but each specific condition affects only tens to hundreds of individuals, making it difficult to recruit participants for clinical trials. Consequently, pharmaceutical companies are hesitant to invest in treatments for a very small patient population due to uncertain returns on investment.

The THRIVE Project: A Spark of Hope

ARPA-H, under the US Department of Health, has recently selected seven research teams to participate in 'THRIVE,' a program focused on developing personalized treatments for rare genetic diseases. This project aims not to create a new drug for each disease, but rather to develop a common gene-editing technology that can be adapted to a patient's specific genetic mutation. The research teams are working towards the following goals:

• Developing gene-editing technology
• Creating delivery vehicles to target specific organs
• Developing manufacturing processes

Through these common technologies, it is expected that development time and costs can be significantly reduced.

A Challenge for the Future: Not Afraid of Failure

The THRIVE project goes beyond simply creating treatments; its goal is to develop therapies applicable to multiple diseases. ARPA-H focuses on supporting high-risk research and operates with agility, ready to adjust funding or direction immediately if progress falls short. This represents an innovative approach to effective research support.

The Launch of a Korean ARPA-H Project

Starting in 2024, South Korea will also launch its own 'Korean ARPA-H Project,' modeled after the US ARPA-H. The Ministry of Health and Welfare and the Korea Health Industry Development Institute will collaborate to promote research projects aimed at solving various health issues, including infectious diseases, cancer, and rare diseases. These initiatives aim to address problems that have been overlooked due to small patient numbers and to foster the development of technologies applicable to a wide range of diseases.

We hope that these efforts will bear fruit, leading to a future where a treatment developed for one patient can eventually benefit others. This initiative by the US government appears to be setting a new paradigm in rare disease treatment, extending beyond mere drug development.